Compare Abbott Laboratories (ABT) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Yum! Brands, Inc. — how do they compare? Abbott Laboratories trades at $111.22 (market cap $187.95B), while Yum! Brands, Inc. trades at $150.2 (market cap $39.50B). The key difference: Abbott Laboratories is far larger — about 4.8× Yum! Brands, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | YUM | |
|---|---|---|
Market Cap | $187.95B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $168.16 |
52-Week Low | $82.57 | $138.21 |
Enterprise Value | $214.96B | $51.10B |
Dividend Yield | 2.32% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
YUM Brands trades at $148.91, up 2.46% with recent earnings beats offset by food safety concerns. Technical indicators show bearish momentum with support at $141, while fundamentals reveal strong revenue growth to $8.21B in 2025 and net income of $1.56B. The company recently completed the $1.2B sale of Pizza Hut China, streamlining operations amid cyclospora outbreak impacts on Taco Bell sales.
YUM presents a mixed outlook with 37% analyst buy ratings and $174.60 price target suggesting 17% upside, but faces near-term headwinds from food safety investigations and consumer sentiment. Long-term growth depends on KFC/Taco Bell execution and digital strategy success amid elevated debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
